et al., Stable gastric pentadecapeptide BPC 157: novel therapy in gastrointestinal tract , Current Pharmaceutical Design, 2011
B12 from food and supplements has to pass through a fairly involved process in the stomach and gut before your body can use it, and that process becomes less efficient with age, with certain medications, and with diets that include little or no animal protein
Single-Mechanism Peptides AOD 9604: Modified fragment of growth hormone Targets fat metabolism without affecting blood sugar Modest weight loss effects (typically 2-6%) Minimal side effects AOD 9604 research shows promise for targeted fat reduction 5-Amino-1MQ: Inhibits NNMT enzyme to boost NAD+ levels Enhances cellular metabolism and energy production Supports weight management through metabolic optimization Well-tolerated with few reported side effects 5-Amino-1MQ research demonstrates metabolic benefits Dual-Mechanism Approaches Tirzepatide (GIP/GLP-1 dual agonist): Activates both GIP and GLP-1 receptors Achieved ~15-22% weight loss in clinical trials FDA-approved for type 2 diabetes and obesity Represents current standard for dual-mechanism therapy CagriSema (Cagrilintide/Semaglutide): Combines amylin and GLP-1 activation Demonstrated 15.6% weight loss in phase 3 trials Regulatory submissions completed in 2024 Establishes proof-of-concept for cagrilintide combinations The Four-Pathway Advantage The theoretical cagrilintide blend with retatrutide would represent the most comprehensive multi-pathway approach studied to date: Receptor Targets: Amylin (cagrilintide) Satiety and gastric emptying GIP (retatrutide) Insulin secretion and fat metabolism GLP-1 (retatrutide) Appetite suppression and glucose control Glucagon (retatrutide) Energy expenditure and fat oxidation This four-pathway activation potentially addresses metabolic health more comprehensively than any existing single agent or combination
One of the primary ways tirzepatide produces weight loss is through appetite reduction
This regenerative approach may be appropriate for men who: Have stable or early-stage Peyronies disease Are seeking a non-surgical alternative Wish to avoid penile implants or invasive surgery Have persistent curvature, plaque, or ED symptoms A comprehensive consultation and ultrasound evaluation are essential to determine candidacy
Post-protocol maintenance After completing an initial protocol, some researchers use lower-frequency maintenance dosing (BPC-157 once daily or every other day, TB-500 once weekly) for an additional 4 to 6 weeks
